Efficient [18F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors

Bioconjugate Chemistry

Volumn 27, Issue 8, 2016, Pages 1839-1849

  Da Pieve, Chiara ^a   Allott, Louis ^a   Martins, Carlos D ^a   Vardon, Andrew ^a   Ciobota, Daniela M ^a   Kramer Marek, Gabriela ^a   Smith, Graham ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; DISEASES; INVERSE PROBLEMS; MOLECULES; TUMORS;

AFFIBODY MOLECULES; CANCER CELLS; EPIDERMAL GROWTH FACTOR RECEPTORS; FUNCTIONALIZED; HUMAN EPIDERMAL GROWTH FACTOR; IN-VIVO; PATIENT PROGNOSIS; RADIOLABELLING; RECEPTOR CELLS; TRIAZACYCLONONANE;

CHELATION;

1,4,7 TRIAZACYCLONONANE 1,4 DIACETATE; 1,4,7 TRIAZANONANE 1,4,7 TRIACETATE; ALUMINUM FLUORIDE; ALUMINUM FLUORIDE F 18; CHELATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FLUORINE 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 1,4,7-TRIAZACYCLONONANE-N,N',N''-TRIACETIC ACID; ALUMINUM; ERBB3 PROTEIN, HUMAN; FLUORINE; HETEROCYCLIC COMPOUND; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONJUGATE; CONTROLLED STUDY; DIELS ALDER REACTION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; MCF 7 CELL LINE; MOLECULAR IMAGING; MOUSE; NONHUMAN; ONE POT SYNTHESIS; PROTEIN STABILITY; RECEPTOR BINDING; ROOM TEMPERATURE; TUMOR XENOGRAFT; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; MCF-7 CELL LINE; METABOLISM; MOLECULAR MODEL; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROTEIN CONFORMATION;

ALUMINUM; ANIMALS; ANTIBODIES, MONOCLONAL; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FLUORINE RADIOISOTOPES; HETEROCYCLIC COMPOUNDS; HUMANS; ISOTOPE LABELING; MCF-7 CELLS; MICE; MODELS, MOLECULAR; POSITRON-EMISSION TOMOGRAPHY; PROTEIN CONFORMATION; PROTEIN STABILITY; RECEPTOR, ERBB-3;

EID: 84983437097     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.6b00259     Document Type: Article

References (49)

1. Jiang, N., Saba, N. F., and Chen, Z. G. (2012) Advances in targeting HER3 as an anticancer therapy Chemother. Res. Pract. 2012, 1 10.1155/2012/817304
2. Marmor, M. D., Skaria, K. B., and Yarden, Y. (2004) Signal transduction and oncogenesis by ErbB/HER receptors Int. J. Radiat. Oncol., Biol., Phys. 58, 903-913 10.1016/j.ijrobp.2003.06.002
3. Hsieh, A. C. and Moasser, M. M. (2007) Targeting HER proteins in cancer therapy and the role of the non-target HER3 Br. J. Cancer 97, 453-457 10.1038/sj.bjc.6603910
4. Mujoo, K., Choi, B.-K., Huang, Z., Zhang, N., and An, Z. (2014) Regulation of ERBB3/HER3 signaling in cancer Oncotarget 5, 10222-10236 10.18632/oncotarget.2655
5. Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., and Hynes, N. E. (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation Proc. Natl. Acad. Sci. U. S. A. 100, 8933-8938 10.1073/pnas.1537685100
6. Baselga, J. and Swain, S. M. (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Nat. Rev. Cancer 9, 463-475 10.1038/nrc2656
7. Campbell, M. R., Amin, D., and Moasser, M. M. (2010) HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy Clin. Cancer Res. 16, 1373-1383 10.1158/1078-0432.CCR-09-1218
8. Lee-Hoeflich, S. T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., and Stern, H. M. (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy Cancer Res. 68, 5878-5887 10.1158/0008-5472.CAN-08-0380
9. Navolanic, P. M., Steelman, L. S., and McCubrey, J. A. (2003) EGFR family signaling and its association with breast cancer development and resistance to chemotherapy Int. J. Oncol. 22, 237-252 10.3892/ijo.22.2.237
10. Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., and Moasser, M. M. (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Nature 445, 437-441 10.1038/nature05474
11. Kruser, T. J. and Wheeler, D. L. (2010) Mechanisms of resistance to HER family targeting antibodies Exp. Cell Res. 316, 1083-1100 10.1016/j.yexcr.2010.01.009
12. Schoeberl, B., Faber, A. C., Li, D., Liang, M.-C., Crosby, K., Onsum, M., Burenkova, O., Pace, E., Walton, Z., and Nie, L. et al. 2010, An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation Cancer Res. 70, 2485-2494 10.1158/0008-5472.CAN-09-3145
13. Schaefer, G., Haber, L., Crocker, L. M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C. V., and Stawicki, S. et al. 2011, A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies Cancer Cell 20, 472-486 10.1016/j.ccr.2011.09.003
14. LoRusso, P., Jänne, P. A., Oliveira, M., Rizvi, N., Malburg, L., Keedy, V., Yee, L., Copigneaux, C., Hettmann, T., and Wu, C. et al. 2013, Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors Clin. Cancer Res. 19, 3078-3087 10.1158/1078-0432.CCR-12-3051
15. Meulendijks, D., Jacob, W., Martinez-Garcia, M., Taus, A., Lolkema, M. P., Voest, E. E., Langenberg, M. H. G., Kanonnikoff, T. F., Cervantes, A., and De Jonge, M. J. et al. 2016, First-in-human Phase I study of Lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors Clin. Cancer Res. 22, 877-885 10.1158/1078-0432.CCR-15-1683
16. 89Zr-RG7116 mAbs 6, 1051-1058 10.4161/mabs.29097
17. 64Cu]DOTA-Patritumab to assess dosimetry, apparent receptor occupancy, and safety in subjects with advanced solid tumors Mol. Imaging Biol. 18, 446-453 10.1007/s11307-015-0912-y
18. Wehrenberg-Klee, E., Turker, N. S., Heidari, P., Larimer, B., Juric, D., Baselga, J., Scaltriti, M., and Mahmood, U. (2016) Differential receptor tyrosine kinase PET imaging for therapeutic guidance J. Nucl. Med. 10.2967/jnumed.115.169417
19. Göstring, L., Malm, M., Höidén-Guthenberg, I., Frejd, F. Y., Ståhl, S., Löfblom, J., and Gedda, L. (2012) Cellular effects of HER3-specific affibody molecules PLoS One 7, e40023 10.1371/journal.pone.0040023
20. Orlova, A., Feldwisch, J., Abrahmsén, L., and Tolmachev, V. (2007) Affibody molecules for molecular imaging and therapy for cancer Cancer Biother.Radiopharm. 22, 573-584 10.1089/cbr.2006.004-U
21. Malm, M., Kronqvist, N., Lindberg, H., Gudmundsdotter, L., Bass, T., Frejd, F. Y., Höidén-Guthenberg, I., Varasteh, Z., Orlova, A., and Tolmachev, V. et al. 2013, Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification PLoS One 8, e62791 10.1371/journal.pone.0062791
22. HER3:08699 affibody molecule Eur. J. Nucl. Med. Mol. Imaging 41, 1450-1459 10.1007/s00259-014-2733-7
23. Andersson, K. G., Rosestedt, M., Varasteh, Z., Malm, M., Sandström, M., Tolmachev, V., Löfblom, J., Ståhl, S., and Orlova, A. (2015) Comparative evaluation of 111In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors Oncol. Rep. 34, 1042-1048 10.3892/or.2015.4046
24. Robinson, M. K., Hodge, K. M., Horak, E., Sundberg, Å. L., Russeva, M., Shaller, C. C., von Mehren, M., Shchaveleva, I., Simmons, H. H., and Marks, J. D. et al. 2008, Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro Br. J. Cancer 99, 1415-1425 10.1038/sj.bjc.6604700
25. Tolmachev, V., Wållberg, H., Sandström, M., Hansson, M., Wennborg, A., and Orlova, A. (2011) Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels Eur. J. Nucl. Med. Mol. Imaging 38, 531-539 10.1007/s00259-010-1646-3
26. 18F-radiolabeling of biomolecules for radionuclide-based in vivo imaging Bioconjugate Chem. 26, 1000-1003 10.1021/acs.bioconjchem.5b00180
27. 18F radiolabeling for PET J. Nucl. Med. 50, 991-998 10.2967/jnumed.108.060418
28. Jacobson, O., Kiesewetter, D. O., and Chen, X. (2015) Fluorine-18 radiochemistry, labeling strategies and synthetic routes Bioconjugate Chem. 26, 1-18 10.1021/bc500475e
29. 2 for tumor angiogenesis PET imaging Eur. J. Nucl. Med. Mol. Imaging 38, 1732-1741 10.1007/s00259-011-1847-4
30. 18F) EJNMMI Res. 3, 36 10.1186/2191-219X-3-36
31. Niu, G., Lang, L., Kiesewetter, D. O., Ma, Y., Sun, Z., Guo, N., Guo, J., Wu, C., and Chen, X. (2014) In vivo labeling of serum albumin for PET J. Nucl. Med. 55, 1150-1156 10.2967/jnumed.114.139642
32. HER2:2395 in a mouse model for ovarian cancer J. Nucl. Med. 53, 146-153 10.2967/jnumed.111.093047
33. HER2:2891 including preclinical assessment J. Nucl. Med. 54, 1981-1988 10.2967/jnumed.113.122465
34. 18F-labeled affibodies for PET imaging of EGFR positive tumors Mol. Pharmaceutics 11, 3947-3956 10.1021/mp5003043
35. 18F-Based pretargeted PET imaging based on biorthogonal Diels-Alder click chemistry Bioconjugate Chem. 27, 298-301 10.1021/acs.bioconjchem.5b00504
36. 18F chelation Bioconjugate Chem. 22, 1793-1803 10.1021/bc200175c
37. 18F]AlF method Appl. Radiat. Isot. 70, 200-2004 10.1016/j.apradiso.2011.08.013
38. Kiesewetter, D. O., Kramer-Marek, G., Ma, Y., and Capala, J. (2008) Radiolabeling of HER2 specific Affibody® molecule with F-18 J. Fluorine Chem. 129, 799-805 10.1016/j.jfluchem.2008.06.021
39. Knall, A.-C. and Slugovc, C. (2013) Inverse electron demand Diels-Alder (iEDDA)-initiated conjugated: a (high) potential click chemistry scheme Chem. Soc. Rev. 42, 5131-5142 10.1039/c3cs60049a
40. Jewett, J. C. and Bertozzi, C. R. (2010) Cu-free click cycloaddition reactions in chemical biology Chem. Soc. Rev. 39, 1272-1279 10.1039/b901970g
41. 18F-labeling study Chem. Commun. 47, 9732-9734 10.1039/c1cc13151f
42. Gong, H., Kovar, J., Little, G., Chen, H., and Olive, D. M. (2010) In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific affibody molecule labeled with a near-infrared fluorophore Neoplasia 12, 139-149 10.1593/neo.91446
43. Yang, J., Karver, M. R., Li, W., Sahu, S., and Devaraj, N. K. (2012) Metal-catalyzed one-pot synthesis of tetrazines directly from aliphatic nitriles and hydrazine Angew. Chem., Int. Ed. 51, 5222-5225 10.1002/anie.201201117
44. Selvaraj, R. and Fox, J. M. (2013) trans-Cyclooctene-a stable, voracious dienophile for bioorthogonal labeling Curr. Opin. Chem. Biol. 17, 753-760 10.1016/j.cbpa.2013.07.031
45. Löfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Ståhl, S., and Frejd, F. Y. (2010) Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications FEBS Lett. 584, 2670-2680 10.1016/j.febslet.2010.04.014
46. Singh, J. K., Solanki, A., Maniyar, R. C., Banerjee, D., and Shirsath, V. S. (2012) Rapid equilibrium dialysis (RED): an in-vitro high-troughput screening technique for plasma protein binding using human and rat plasma. J. Bioequivalence Bioavailability S14, DOI: 10.4172/jbb.S4114-4005.
47. Behr, T. M., Goldenberg, D. M., and Becker, W. (1998) Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations Eur. J. Nucl. Med. Mol. Imaging 25, 201-212 10.1007/s002590050216
48. Rosestedt, M., Andersson, K. G., Mitran, B., Tolmachev, V., Löfblom, J., Orlova, A., and Ståhl, S. (2015) Affibody-mediated PET imaging of HER3 expression in malignant tumours Sci. Rep. 5, 15226 10.1038/srep15226
49. Workman, P., Aboagye, E. O., Balkwill, F., Balmain, A., Bruder, G., Chaplin, D. J., Double, J. A., Everitt, J., Farningham, D. A. H., and Glennie, M. J. et al. 2010, Guidelines for the welfare and use of animals in cancer research Br. J. Cancer 102, 1555-1577 10.1038/sj.bjc.6605642